Lixte Biotechnology Holdings Inc
NASDAQ:LIXT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
BrainAurora Medical Technology Ltd
HKEX:6681
|
CN |
Lixte Biotechnology Holdings Inc
Total Current Liabilities
Lixte Biotechnology Holdings Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Lixte Biotechnology Holdings Inc
NASDAQ:LIXT
|
Total Current Liabilities
$1.3m
|
CAGR 3-Years
51%
|
CAGR 5-Years
43%
|
CAGR 10-Years
16%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$43.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$11.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$25.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Liabilities
$4.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
18%
|
|
Lixte Biotechnology Holdings Inc
Glance View
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company. The company is headquartered in East Setauket, New York and currently employs 3 full-time employees. The company went IPO on 2007-09-21. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and encompasses two categories of compounds at various stages of pre-clinical and clinical development that has the therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. The firm has developed two series of pharmacologically active drugs, the LB-100 series and the LB-200 series. The LB-100 series consists of structures, which is treated not only several types of cancer but also vascular and metabolic diseases. The LB-200 series contains compounds, which are useful for the treatment of chronic hereditary diseases.
See Also
What is Lixte Biotechnology Holdings Inc's Total Current Liabilities?
Total Current Liabilities
1.3m
USD
Based on the financial report for Dec 31, 2025, Lixte Biotechnology Holdings Inc's Total Current Liabilities amounts to 1.3m USD.
What is Lixte Biotechnology Holdings Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
16%
Over the last year, the Total Current Liabilities growth was 317%. The average annual Total Current Liabilities growth rates for Lixte Biotechnology Holdings Inc have been 51% over the past three years , 43% over the past five years , and 16% over the past ten years .
